PrimeRFP
PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50124F61017PCC and — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 75A50122D00002. PoP ended Jul 15, 2025 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Barda - Aspr / Daappo / Barda Dcma
Awarding office
Glaxosmithkline LLC
Recipient
Jul 15, 2025
PoP end
$144K
Obligated
$144K
Potential
541714
NAICS
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal
Contract number75A50124F61017
Also listed as75A50122D00002-75A50124F61017
AgencyBarda - Aspr / Daappo / Barda Dcma
Awarding officeBarda - Aspr / Daappo / Barda Dcma
Awarding agencyDepartment of Health and Human Services (HHS)
Funding agencyDepartment of Health and Human Services (HHS)
IncumbentGlaxosmithkline LLC
CAGE667E9
UEIFRHTPHMZMX47
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV75A50122D00002
Place of performanceDURHAM NC
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startSep 23, 2024
PoP end (current)Jul 15, 2025
Obligated$144K
Current value$144K
Potential value$144K

Task Order Establishing Physical and Chemical Compatibility (PCC) Study for Acquired Influenza A/Astrakhan/3212/2020 (H… is a federal award for Barda - Aspr / Daappo / Barda Dcma held by Glaxosmithkline LLC. Estimated value $144K ($144K obligated). Current period of performance ends Jul 15, 2025. Place of performance: DURHAM NC.

Task order establishing physical and chemical compatibility (pcc) study for acquired influenza a/astrakhan/3212/2020 (h5n8) antigen combined with mf59 adjuvant or as03 adjuvant. Latest action is a modification.

Recompete timing

Public
● Past PoP end (460 days ago)

Current PoP ended Jul 15, 2025 (460 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Want the durability read on 75A50124F61017? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies
Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%
Open full company profile →

Related awards

Same parent · incumbent
75A50126F61020
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…
$493K
Oct 29, 2026
15F06724F0001366
GSK TRAVEL VACCINES
$115K
Dec 31, 2026
15F06726F0000234
GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187
$113K
Dec 31, 2026
75A50124F61014
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …
$18.4M
Feb 21, 2027
75A50124F61013
THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) …
$15.4M
Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75A50124F61017?

75A50124F61017 (PCC and) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $144K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50124F61017?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50124F61017 to Glaxosmithkline LLC (potential $144K).

Who is the incumbent on 75A50124F61017?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Jul 15, 2025.

When does Glaxosmithkline LLC’s 75A50124F61017 come up for recompete?

SCOUT tracks a period-of-performance end of Jul 15, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75A50124F61017? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50124F61017